13 October 2016 
EMA/CHMP/647568/2016  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Lucentis 
ranibizumab 
On 13 October 2016, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Lucentis. The marketing authorisation holder for this medicinal product is Novartis Europharm Ltd. 
The CHMP adopted an extension to an existing indication as follows2: 
“Lucentis is indicated in adults for: 
• 
The treatment of neovascular (wet) age-related macular degeneration (AMD) 
•  The treatment of visual impairment due to choroidal neovascularisation (CNV) 
• 
• 
• 
The treatment of visual impairment due to diabetic macular oedema (DME) 
The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch 
RVO or central RVO) 
The treatment of visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic 
myopia (PM).” 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
